跳轉至內容
Merck
  • Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

The Journal of membrane biology (2014-12-24)
Tomaz Mars, Marusa Strazisar, Katarina Mis, Nejc Kotnik, Katarina Pegan, Jasna Lojk, Zoran Grubic, Mojca Pavlin
摘要

Transfection of primary human myoblasts offers the possibility to study mechanisms that are important for muscle regeneration and gene therapy of muscle disease. Cultured human myoblasts were selected here because muscle cells still proliferate at this developmental stage, which might have several advantages in gene therapy. Gene therapy is one of the most sought-after tools in modern medicine. Its progress is, however, limited due to the lack of suitable gene transfer techniques. To obtain better insight into the transfection potential of the presently used techniques, two non-viral transfection methods--lipofection and electroporation--were compared. The parameters that can influence transfection efficiency and cell viability were systematically approached and compared. Cultured myoblasts were transfected with the pEGFP-N1 plasmid either using Lipofectamine 2000 or with electroporation. Various combinations for the preparation of the lipoplexes and the electroporation media, and for the pulsing protocols, were tested and compared. Transfection efficiency and cell viability were inversely proportional for both approaches. The appropriate ratio of Lipofectamine and plasmid DNA provides optimal conditions for lipofection, while for electroporation, RPMI medium and a pulsing protocol using eight pulses of 2 ms at E = 0.8 kV/cm proved to be the optimal combination. The transfection efficiencies for the optimal lipofection and optimal electrotransfection protocols were similar (32 vs. 32.5%, respectively). Both of these methods are effective for transfection of primary human myoblasts; however, electroporation might be advantageous for in vivo application to skeletal muscle.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
磷酸钾 一元, ACS reagent, ≥99.0%
Sigma-Aldrich
磷酸钾二元 二元, ACS reagent, ≥98%
Sigma-Aldrich
磷酸钾 一元, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
L -还原型谷胱甘肽, suitable for cell culture, BioReagent, ≥98.0%, powder
Sigma-Aldrich
磷酸钾 一元, buffer substance, anhydrous, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5-100.5%
Sigma-Aldrich
磷酸钾二元 二元, puriss. p.a., ACS reagent, anhydrous, ≥99.0% (T)
Sigma-Aldrich
磷酸钾 一元, meets analytical specification of Ph. Eur., NF, E340, anhydrous, 98-100.5% (calc. to the dried substance)
Sigma-Aldrich
磷酸钾 一元, for molecular biology, ≥98.0%
Sigma-Aldrich
磷酸钾二元 二元, anhydrous, for luminescence, for molecular biology, BioUltra, ≥99.0% (T)
Sigma-Aldrich
磷酸钾 二元 溶液, 1.0 M
Sigma-Aldrich
磷酸钾 一元, BioUltra, for molecular biology, anhydrous, ≥99.5% (T)
Sigma-Aldrich
L -还原型谷胱甘肽, ≥98.0%
Sigma-Aldrich
磷酸钾 一元, 99.99% trace metals basis
Sigma-Aldrich
磷酸钾二元 二元, 99.95% trace metals basis
Sigma-Aldrich
磷酸钾 一元, ReagentPlus®
USP
磷酸二氢钾, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
磷酸钾二元 二元, reagent grade, ≥98.0%
Supelco
谷胱甘肽, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
磷酸钾 二元, meets USP testing specifications
Sigma-Aldrich
L -还原型谷胱甘肽, BioXtra, ≥98.0%
Supelco
磷酸二氢钾, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
磷酸钾 一元, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
磷酸钾 一元, Vetec, reagent grade, 99%
谷胱甘肽, European Pharmacopoeia (EP) Reference Standard